<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00524615</url>
  </required_header>
  <id_info>
    <org_study_id>ASPIRANT-1</org_study_id>
    <secondary_id>EudraCT 2007-003558-27</secondary_id>
    <nct_id>NCT00524615</nct_id>
  </id_info>
  <brief_title>Addition of Spironolactone in Patients With Resistant Arterial Hypertension</brief_title>
  <acronym>ASPIRANT</acronym>
  <official_title>Addition of Spironolactone in Patients With Resistant Arterial Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jan Vaclavík</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Czech Society of Hypertension</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Prostejov Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Brno University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Olomouc Military Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gedeon Richter Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Olomouc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of spironolactone on lowering blood
      pressure when added to therapy in patients with resistant arterial hypertension.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Arterial hypertension resistant to therapy and requiring treatment with more then three
      antihypertensive drugs is common. At present there are is no standard therapy for resistant
      hypertension based on randomised clinical trials, neither data to guide addition of further
      drugs to therapy. Recently some observational and retrospective trials reported good effect
      of spironolactone in patients with resistant hypertension, but these data were not validated
      by prospective randomised clinical trials.

      This is a multicentric, randomised, double blind clinical trial, which will evaluate the
      effect of addition of 25 mg spironolactone to current medication compared to placebo. The
      study will enroll patients with blood pressure over 140/90 mmHg during a clinical
      examination, which are using at least three antihypertensive drugs, one of them being a
      diuretic. Average daytime systolic and diastolic blodd pressure will be evaluated by ABPM
      (ambulatory blood pressure monitoring).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2007</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Average daytime systolic and diastolic blodd pressure evaluated by ABPM (ambulatory blood pressure monitoring)</measure>
    <time_frame>before and after 2 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes of serum potassium, natrium, creatinine, body weight, casual blood pressure in office, treatment response for different baseline levels of aldosterone and aldosterone/PRA ratio</measure>
    <time_frame>2 months of follow-up</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg of Spironolactone oraly once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo oraly once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>spironolactone</intervention_name>
    <description>25 mg of spironolactone once daily or placebo for 2 months</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients over 18 years

          -  Resistant arterial hypertension: (blood pressure during clinical control exceeding
             140/90 mmHg (or 130/80 mmHg in in diabetic patients or patients with renal disease
             with creatinine level of more than 133 μmol per liter or urinary protein excretion of
             more than 300 mg over a 24-hour period) despite adherence to treatment with full doses
             of at least three antihypertensive medications, including a diuretic

        Exclusion Criteria:

          -  Pregnant or breastfeeding women, women in fertile age without ruled out pregnancy

          -  Severe hypertension over 180/110 mmHg

          -  Renal insufficiency with creatinine over 180 umol/l or GFR lower than 40 ml/min

          -  Hyperkalemia over 5,4 mmol/l, hyponatremia below 130 mmol/l

          -  Porphyria

          -  Hypersensitivity to the compounds of Verospiron (Richter Gedeon, Hungary) drug

          -  Patients taking any aldosterone antagonist (spironolactone, eplerenone, kanreone)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Václavík, MD.</last_name>
    <role>Study Director</role>
    <affiliation>Internal medicine department I, Olomouc university hospital and Palacký University School of medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bořek Lačňák, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal Medicine Dept., Šternberk Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martin Plachý, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Internal medicine department II, Brno University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Václavík, MD.</last_name>
    <phone>+420588443209</phone>
    <email>vaclavk.j@centrum.cz</email>
  </overall_contact>
  <location>
    <facility>
      <name>Olomouc University Hospital and Palacký University School of Medicine</name>
      <address>
        <city>Olomouc</city>
        <zip>775 20</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Václavík, MD.</last_name>
    </contact>
    <investigator>
      <last_name>Jan Václavík, MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <link>
    <url>http://www.lf.upol.cz/en/</url>
    <description>Palacký University School of Medicine</description>
  </link>
  <link>
    <url>http://www.fnol.cz/</url>
    <description>Olomouc University Hospital</description>
  </link>
  <reference>
    <citation>Chapman N, Dobson J, Wilson S, Dahlöf B, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007 Apr;49(4):839-45. Epub 2007 Feb 19.</citation>
    <PMID>17309946</PMID>
  </reference>
  <reference>
    <citation>Sharabi Y, Adler E, Shamis A, Nussinovitch N, Markovitz A, Grossman E. Efficacy of add-on aldosterone receptor blocker in uncontrolled hypertension. Am J Hypertens. 2006 Jul;19(7):750-5.</citation>
    <PMID>16814132</PMID>
  </reference>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 31, 2007</study_first_submitted>
  <study_first_submitted_qc>August 31, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2007</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Olomouc</investigator_affiliation>
    <investigator_full_name>Jan Vaclavík</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>resistant hypertension treatment</keyword>
  <keyword>spironolactone</keyword>
  <keyword>aldosterone antagonists</keyword>
  <keyword>resistant arterial hypertension</keyword>
  <keyword>refractory arterial hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>December 22, 2015</submitted>
    <returned>January 28, 2016</returned>
    <submitted>January 28, 2016</submitted>
    <returned>February 26, 2016</returned>
    <submitted>September 5, 2017</submitted>
    <returned>March 30, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

